How suitable are available pharmaceuticals for the treatment of sexually transmitted diseases? 1: Conditions presenting as genital discharges.
The relative prevalence of sexually transmitted diseases and the agents available for the treatment of these diseases commonly presenting as genital discharges-namely, gonorrhoea, candidosis, trichomoniasis, and non-specific genital infection-are reviewed. The many agents that are active against gonorrhoea are listed, but none is ideal. Penicillin, in spite of its allergic side effects, has remained the drug of choice for 25 years because it is cheap, easily obtained, lacks toxicity even in pregnancy, and is effective. Its use is now threatened by the emergence of some strains that are able to produce penicillinase. At present the policy is to obtain the best results from penicillin while these are acceptable, but the clinician in some countries is badly served by the availability of procaine penicillin in aqueous suspension. There is a need for an effective penicillin or cephalosporin that is penicillinase resistant and cheap. Cefuroxime offers considerable hope but it is likely to be expensive in the immediate future.There are many preparations for the local treatment of candidosis. The confidence expressed by the manufacturers in recommending a three-day treatment is, it is hoped, based on a superior product. Nevertheless there is a need for a safe systemically absorbed fungicide which could be used orally, or some substance that could render the vagina an inhospitable environment for the organism.In the treatment of trichomoniasis the pharmaceutical industry in providing substances more than 90% effective in a single dose has done all that can be expected. Any further advances lie in the field of human behaviour rather than pharmaceutical research.In the treatment of non-specific genital infection the needs are more of research than of therapy. More knowledge is required of the cause of the condition and the relative role of contending pathogens, and of the results of treatment of patients and contacts in which Chlamydia or other suspect pathogens have been isolated.
D002177:Candidiasis / Q000188:drug therapy* / Q000453:epidemiology; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008297:Male; D010403:Penicillin Resistance; D010405:Penicillinase / Q000096:biosynthesis; D010406:Penicillins / Q000627:therapeutic use; D012749:Sexually Transmitted Diseases / Q000188:drug therapy*; D014245:Trichomonas Infections / Q000188:drug therapy* / Q000453:epidemiology; D014247:Trichomonas Vaginitis / Q000188:drug therapy; D014526:Urethritis / Q000188:drug therapy
D010406:Penicillins; D010405:Penicillinase